| Code | CSB-RA009892MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ginisortamab, targeting GREM1 (Gremlin-1), a secreted BMP antagonist and member of the DAN family of cysteine knot proteins. GREM1 functions as a key regulator of embryonic development and tissue differentiation by binding and inhibiting bone morphogenetic proteins (BMPs), particularly BMP2, BMP4, and BMP7. Dysregulated GREM1 expression has been implicated in various pathological conditions, including fibrotic diseases, hereditary mixed polyposis syndrome, and multiple cancers where it promotes tumor progression, metastasis, and angiogenesis through modulation of BMP signaling and activation of VEGF pathways.
Ginisortamab represents an investigational therapeutic antibody designed to neutralize GREM1 activity, with potential applications in oncology and fibrosis research. This biosimilar antibody provides researchers with a valuable tool for investigating GREM1-mediated signaling mechanisms, studying BMP pathway regulation, and exploring therapeutic interventions in GREM1-associated diseases. It enables experimental studies of GREM1 blockade in preclinical models and facilitates the characterization of GREM1's role in disease pathogenesis.
There are currently no reviews for this product.